**Antimicrobial Use and Resistance (AUR): Pharmacy Data**

**Monthly Electronic Upload Specification Tables**

*These data will be collected in an aggregate monthly electronic file transfer from the facility to NHSN via Clinical Document Architecture (CDA).*

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 1. CDA File Descriptors** | | | | *These data elements will be transmitted with each month’s report.* | | | | | | | |
| **Variable Name** | | Description of Variable | | | | | | | | | |
| Facility OID | | NHSN Facility ID number | | | | | | | | | |
| Application OID | | Vendor software ID number | | | | | | | | | |
| SDS validation ID | | ID provided by NHSN Team confirming vendor software passed validation | | | | | | | | | |
| location | | NHSN location code | | | | | | | | | |
| month | | Denominator month | | | | | | | | | |
| year | | Denominator year | | | | | | | | | |
| **Table 2. Aggregate Patient Information** | | | | | *These data elements are aggregated to the location and facility wide inpatient level for each month.* | | | | | | |
| **Variable Name** | | Description of Variable | | | | | | | | | |
| numDaysPresent | | Total number of days present | | | | | | | | | |
| numTherapyDays | | Number of therapy days | | | | | | | | | |
| numAdmissions | | Number of admissions | | | | | | | | | |
| **Table 3. Aggregate Pharmacy Information** | | | | | | *These data elements are obtained from the facility’s electronic medication administration record (eMAR) or bar coding medication administration (BCMA) and aggregated to the location and facility wide inpatient level for each month.* | | | | | |
| **Variable Name** | | Description of Variable | | | | | Examples | | | | |
| drugIngredient | | Antimicrobial ingredient | | | | | (see Table 3a) | | | | |
| routeDrugAdmin | | Route of administration | | | | | Digestive tract, respiratory tract, intravenous route, intramuscular route | | | | |
| **Table 3a. List of Antimicrobials Accepted** | | | | | | *This is the list of antimicrobials currently accepted into NHSN as part of the antimicrobial use reporting.* | | | | | |
| Amantadine | Baloxavir marboxil | | Cefpodoxime | | Colistimethate | | | Fosfomycin | Micafungin | Peramivir | Telavancin |
| Amikacin | Caspofungin | | Cefprozil | | Colistin | | | Gemifloxacin | Minocycline | Piperacillin/ Tazobactam | Tetracycline |
| Amikacin Liposomal | Cefaclor | | Ceftaroline | | Dalbavancin | | | Gentamicin | Molnupiravir | Pivmecillinam | Tigecycline |
| Amoxicillin | Cefadroxil | | Ceftazidime | | Daptomycin | | | Imipenem/ Cilastatin | Moxifloxacin | Plazomicin | Tinidazole |
| Amoxicillin/ Clavulanate | Cefazolin | | Ceftazidime/ Avibactam | | Delafloxacin | | | Imipenem/ Cilastatin/ Relebactam | Nafcillin | Polymyxin B | Tobramycin |
| Amphotericin B | Cefdinir | | Ceftobiprole medocaril | | Dicloxacillin | | | Isavuconazonium | Nirmatrelvir | Posaconazole | Vancomycin |
| Amphotericin B lipid complex | Cefepime | | Ceftolozane/ Tazobactam | | Doxycycline | | | Itraconazole | Nitrofurantoin | Quinupristin/ Dalfopristin | Voriconazole |
| Amphotericin B liposomal | Cefepime/ Enmetazobactam | | Ceftriaxone | | Eravacycline | | | Lefamulin | Omadacycline | Remdesivir | Zanamivir |
| Ampicillin | Cefiderocol | | Cefuroxime | | Ertapenem | | | Levofloxacin | Oritavancin | Rezafungin |  |
| Ampicillin/ Sulbactam | Cefixime | | Cephalexin | | Erythromycin | | | Linezolid | Oseltamivir | Rifampin |  |
| Anidulafungin | Cefotaxime | | Ciprofloxacin | | Etzadroxil/ Probenecid\* | | | Meropenem | Oxacillin | Rimantadine | **\***Addition pending FDA approval of the drug in Sept 2024 |
| Azithromycin | Cefotetan | | Clarithromycin | | Fidaxomicin | | | Meropenem/ Vaborbactam | Penicillin G | Sulfamethoxazole/ Trimethoprim |
| Aztreonam | Cefoxitin | | Clindamycin | | Fluconazole | | | Metronidazole | Penicillin V | Tedizolid |
| **Assurance of Confidentiality:**  The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).  Public reporting burden of this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information.  An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.  Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS H21-8, Atlanta, GA 30333, ATTN:  PRA (0920-0666).  CDC 57.124 v9, 13.0 | | | | | | | | | | | |